Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.2728
-0.0058 (-2.08%)
At close: Jun 5, 2025, 4:00 PM
0.2719
-0.0009 (-0.33%)
Pre-market: Jun 6, 2025, 4:42 AM EDT
Genprex Employees
Genprex had 15 employees as of December 31, 2024. The number of employees decreased by 11 or -42.31% compared to the previous year.
Employees
15
Change (1Y)
-11
Growth (1Y)
-42.31%
Revenue / Employee
n/a
Profits / Employee
-$1,273,793
Market Cap
6.59M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GNPX News
- 2 days ago - Genprex to Participate at BIO 2025 International Convention - PRNewsWire
- 7 days ago - Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - PRNewsWire
- 8 days ago - Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - PRNewsWire
- 4 weeks ago - Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PRNewsWire
- 4 weeks ago - Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PRNewsWire
- 5 weeks ago - Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PRNewsWire
- 5 weeks ago - Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - PRNewsWire
- 5 weeks ago - Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - PRNewsWire